EXAS (Exact Sciences Corp)
Insider Trading Activity
Every open-market purchase and sale reported by EXAS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-23 | Katherine S Zanotti | Director | D | — | — |
| 2026-03-23 | Michael J Barber | Director | D | — | — |
| 2026-03-23 | Kimberly J Popovits | Director | D | — | — |
| 2026-03-23 | Sarah Condella | EVP, Human Resources | MIXED | — | — |
| 2026-03-23 | Paul J Clancy | Director | D | — | — |
| 2026-03-23 | Shacey Petrovic | Director | D | — | — |
| 2026-03-23 | JACOB A ORVILLE | EVP, GM, Screening | MIXED | — | — |
| 2026-03-23 | Leslie Trigg | Director | D | — | — |
| 2026-03-23 | James Edward Doyle | Director | D | — | — |
| 2026-03-23 | D SCOTT COWARD | Director | D | — | — |
| 2026-03-23 | James Herriott | SVP, General Counsel & Sec | D | — | — |
| 2026-03-23 | Kevin T Conroy | President and CEO | MIXED | — | — |
| 2026-03-23 | Aaron Bloomer | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-03-23 | Brian Baranick | EVP, GM, Precision Oncology | MIXED | — | — |
| 2026-03-03 | Sarah Condella | EVP, Human Resources | MIXED | — | — |
| 2026-03-03 | Kevin T Conroy | President and CEO | MIXED | — | — |
| 2026-02-27 | Aaron Bloomer | EVP, Chief Financial Officer | A | — | — |
| 2026-02-27 | JACOB A ORVILLE | EVP, GM, Screening | A | — | — |
| 2026-02-27 | Sarah Condella | EVP, Human Resources | A | — | — |
| 2026-02-27 | Brian Baranick | EVP, GM, Precision Oncology | A | — | — |
| 2026-02-27 | Kevin T Conroy | President and CEO | MIXED | — | — |
| 2026-02-27 | James Herriott | SVP, General Counsel & Sec | A | — | — |
| 2025-12-30 | Aaron Bloomer | EVP, Chief Financial Officer | MIXED | — | — |
| 2025-12-30 | Brian Baranick | EVP, GM, Precision Oncology | MIXED | — | — |
| 2025-12-30 | Kevin T Conroy | President and CEO | MIXED | — | — |
| 2025-12-30 | JACOB A ORVILLE | EVP, GM, Screening | MIXED | — | — |
| 2025-12-30 | Sarah Condella | EVP, Human Resources | MIXED | — | — |
| 2025-12-30 | James Herriott | SVP, General Counsel & Sec | MIXED | — | — |
| 2025-11-21 | James Herriott | SVP, General Counsel & Sec | Sell | — | — |
| 2025-11-21 | JACOB A ORVILLE | EVP, GM, Screening | Sell | — | — |
| 2025-11-06 | Brian Baranick | EVP, GM, Precision Oncology | Sell | — | — |
| 2025-11-06 | James Herriott | SVP, General Counsel & Sec | Sell | — | — |
| 2025-10-27 | Katherine S Zanotti | Director | Sell | — | — |
| 2025-10-10 | James Edward Doyle | Director | Sell | — | — |
| 2025-10-10 | James Herriott | SVP, General Counsel & Sec | Sell | — | — |
| 2025-08-14 | James Edward Doyle | Director | Sell | — | — |
| 2025-08-07 | JACOB A ORVILLE | EVP, GM, Screening | MIXED | — | — |
| 2025-08-07 | Brian Baranick | EVP, GM, Precision Oncology | MIXED | — | — |
| 2025-06-16 | Michael J Barber | Director | A | — | — |
| 2025-06-16 | James Edward Doyle | Director | A | — | — |
| 2025-06-16 | D SCOTT COWARD | Director | A | — | — |
| 2025-06-16 | DANIEL J LEVANGIE | Director | A | — | — |
| 2025-06-16 | Paul J Clancy | Director | A | — | — |
| 2025-06-16 | Leslie Trigg | Director | A | — | — |
| 2025-06-16 | Katherine S Zanotti | Director | MIXED | — | — |
| 2025-06-16 | Shacey Petrovic | Director | A | — | — |
| 2025-06-16 | Kimberly J Popovits | Director | A | — | — |
| 2025-05-08 | James Herriott | SVP, General Counsel & Sec | A | — | — |
| 2025-05-01 | Leslie Trigg | Director | A | — | — |
| 2025-04-17 | Aaron Bloomer | EVP, Chief Financial Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 1,375,290 | — |
| — | COO | 658,613 | — |
| — | Director | 481,939 | — |
| — | President, CEO and Director | 253,702 | — |
| — | Director | 240,109 | — |
| — | Director | 201,095 | — |
| — | EVP, Human Resources | 191,891 | — |
| — | EVP, GM, Precision Oncology | 137,195 | — |
| — | Director | 127,575 | — |
| — | Exec. Chairman & Interim CEO | 124,994 | — |
| — | Director | 97,274 | — |
| — | Director | 80,513 | — |
| — | Director | 78,033 | — |
| — | SVP, Chief Medical Officer | 63,457 | — |
| — | SVP, Finance | 52,369 | — |
| — | General Manager - Diagnostics | 49,884 | — |
| — | Chief Commercial Officer | 47,041 | — |
| — | Chief Science Officer | 43,040 | — |
| — | President, Cologuard | 41,874 | — |
| — | Chief Commercial Officer | 41,718 | — |
| — | Director | 34,312 | — |
| — | Director | 33,767 | — |
| — | Director | 32,671 | — |
| — | Director | 23,576 | — |
| — | Director | 19,688 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EXAS quote page; the site-wide leaderboard is on the insider transactions hub.